Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients

Advances in Therapy

Volumn 30, Issue 8, 2013, Pages 784-791

  Sahin, Deniz Goren ^a   Gunduz, Eren ^a   Kasifoglu, Nilgun ^a   Akay, Olga Meltem ^a   Us, Tercan ^a   Gulbas, Zafer ^b  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b Anadolu Saglik Merkezi Hospital   (Turkey)

Author keywords

CMV DNAemia; Hematopoietic stem cell transplantation; Pre emptive therapy; Real time polymerase chain reaction

Indexed keywords

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; EARLY MEDICAL INTERVENTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LOGISTIC MODELS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RISK FACTORS; SEROLOGIC TESTS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 84894383224     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0049-9     Document Type: Article

References (29)

1. Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9: 543-58.
2. Leruez-Ville M, Ouachee M, Delarue R, et al. Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma. J Clin Microbiol. 2003;41: 2040-6.
3. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325: 1601-7.
4. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118: 173-8.
5. de la Cruz-Vicente F, Perez-Romero P, Aguilar-Guisado M, et al. Differences in cytomegalovirus replication quantified using quantitative polymerase chain reaction and antigenemia after allogeneic stem cell transplantation. Transplant Proc. 2010;42: 3230-1.
6. Farfan UM, Torres TJ, Vergara AA, et al. Comparison of real-time polymerase chain reaction and antigenemia assay to detect cytomegalovirus in pediatric transplants. Rev Chilena Infectol. 2011;28: 113-7.
7. Zhai WJ, Wei JL, Zhao MF, et al. Comparison between CMV quantitative PCR and CMV-pp 65 antigen test for detection of CMV infection in allogeneic hematopoietic stem cell transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17: 1522-6.
8. Choi SM, Lee DG, Lim J, et al. Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp 65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients. J Korean Med Sci. 2009;24: 571-8.
9. Gimeno C, Solano C, Latorre JC, et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol. 2008;46: 3311-8.
10. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25: 151-69.
11. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153: 478-88.
12. Patel SR, Ridwan RU, Ortin M. Cytomegalovirus reactivation in pediatric hemopoietic progenitors transplant: a retrospective study on the risk factors and the efficacy of treatment. J Pediatr Hematol Oncol. 2005;27: 411-5.
13. Zaucha-Prazmo A, Wojcik B, Drabko K, Choma M, Kowalczyk JR. Cytomegalovirus (CMV) infections in children undergoing hematopoietic stem cell transplantation. Pediatr Hematol Oncol. 2005;22: 271-6.
14. Ataman S, Colak D, Gunseren F, et al. Investigation of cytomegalovirus seroepidemiology in Antalya with a population-based cross-sectional study and review of related data in Turkey. Mikrobiyol Bul. 2007;41: 545-55.
15. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20: 202-13.
16. Peres RM, Costa CR, Andrade PD, et al. Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR. BMC Infect Dis. 2010;10:147.
17. Emery V, Zuckerman M, Jackson G, et al. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol. 2013;162: 25-39.
18. Nichols WG, Boeckh M. Recent advances in the therapy and prevention of CMV infections. J Clin Virol. 2000;16: 25-40.
19. de la Camara R, Fernandez-Ranada JM. Increased incidence of CMV infection after allogeneic bone marrow transplantation from unrelated donors but doubts about an increase in CMV-associated disease. Bone Marrow Transplant. 1997;20:181.
20. Takami A, Mochizuki K, Asakura H, et al. High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant. Haematologica. 2005;90: 1290-2.
21. Takenaka K, Gondo H, Tanimoto K, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group. Bone Marrow Transplant. 1997;19: 241-8.
22. Yoon HS, Lee JH, Choi ES, et al. Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors. Pediatr Transplant. 2009;13: 898-905.
23. Walker CM, van Burik JA, De For TE, Weisdorf DJ. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant. 2007;13: 1106-15.
24. Asano-Mori Y, Oshima K, Sakata-Yanagimoto M, et al. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36: 813-9.
25. Zaia JA. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis. 2002;35: 999-1004.
26. Reusser P, Attenhofer R, Hebart H, et al. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood. 1997;89: 3873-9.
27. Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet. 2000;355: 2032-6.
28. Gentile G, Picardi A, Capobianchi A, et al. A prospective study comparing quantitative cytomegalovirus (CMV) polymerase chain reaction in plasma and pp 65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation. BMC Infect Dis. 2006;6:167.
29. Yakushiji K, Gondo H, Kamezaki K, et al. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Bone Marrow Transplant. 2002;29: 599-606.